SLC5A2 and chronic kidney disease: In addition to its antihyperglycemic effect, treatment with a SGLT-2 inhibitor and/or RAS inhibitor provides many benefits to patients with CKD, including reduced albuminuria and proteinuria, delayed CKD progression, and prevention of renal and cardiovascular events and death [1, 8].